Republican Congress "Must Fire Kessler"

19 December 1994

If the Republicans in Congress want to fundamentally change the way Washington works, reining in the Food and Drug Administration must be a top priority, writes James Bovard in the Wall Street Journal. The use of arbitrary powers and intimidation has increased while David Kessler has headed the agency, he says.

The US medical device industry is downsizing at home and increasing overseas operations because of FDA delays, he says. The FDA has failed to reduce intolerable drug approval delays, seized products that could have benefited Americans and cracked down on freedom of speech. Its use of warning letters has grown dramatically, while it has refused to issue clear guidelines or rules for issuing letters. Moreover, he adds, patients are suffering from Dr Kessler's annulment of First Amendment rights. Proposed regulations have not been finalized, but since 1991 companies have been unable to tell doctors of new uses for approved drugs through promotions, and doctors do not learn of cutting-edge treatments. For example, drug companies cannot reprint and offer doctors, free, parts of medical textbooks if they mention off-label uses.

Mr Bovard does not go as far as supporting new House Speaker Newt Gingrich's plan to replace the FDA with an agency staffed by medical entrepreneurs with strict limits on their time in government, but does say Dr Kessler should be removed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight